BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Obicetrapib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Obicetrapib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06496243-401@assetmemo.bio
DTSTAMP:20261121T003109Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Obicetrapib: Phase 2 readout est. (NCT06496243)
DESCRIPTION:Obicetrapib\, phase 2\, Atherosclerotic Cardiovascular Disease.
 \nStudy: Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Level
 s\nEstimated primary completion: November 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/obicetrapib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06496243
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05202509-401@assetmemo.bio
DTSTAMP:20261121T003109Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Obicetrapib: Phase 3 readout est. (NCT05202509)
DESCRIPTION:Obicetrapib\, phase 3\, Atherosclerotic Cardiovascular Disease.
 \nStudy: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapi
 b in Patients With Cardiovascular Disease\nEstimated primary completion: N
 ovember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obicetr
 apib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05202509
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219602-401@assetmemo.bio
DTSTAMP:20261121T003109Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Obicetrapib: Phase 3 readout est. (NCT07219602)
DESCRIPTION:Obicetrapib\, phase 3\, Type 2 Diabetes.\nStudy: A Study to Eva
 luate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or 
 Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering The
 rapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome\nEstim
 ated primary completion: March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/obicetrapib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07219602
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794670-401@assetmemo.bio
DTSTAMP:20261121T003109Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Obicetrapib: Phase 2 readout est. (NCT07794670)
DESCRIPTION:Obicetrapib\, phase 2.\nStudy: Randomized Study to Evaluate the
  Effect of Obicetrapib in Participants With Preclinical Alzheimer's Diseas
 e\nEstimated primary completion: September 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/obicetrapib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07794670
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
